ArticleFrontiers in pediatrics2025
Metanephric adenoma in a pediatric patient case report.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metanephric adenoma (MA) is a rare benign renal tumor, with an incidence of 0.2%-1%. Approximately 90% of MA cases present with the BRAF V600E mutation. This study reports an 8-year-old male child who presented with abdominal pain for one month. Abdominal ultrasound revealed a cystic necrotic mass measuring 56 × 45 mm in the right kidney. A preliminary diagnosis of Wilms tumor (WT) led to the initiation of preoperative vincristine therapy. Right nephroureterectomy was performed by pediatric surgery. Histopathological analysis could not differentiate between MA and WT. Immunohistochemical findings were positive for WT1, PANCK (weak focal), INI1 (intact), PAX8, CD56, and CD57. Genetic testing confirmed the presence of the BRAF V600E mutation (1799T > A, 1799_1800TG > AA). The patient was diagnosed with MA and was followed without chemotherapy. In conclusion, MA, which can be mistaken for WT, should be considered in the differential diagnosis of pediatric renal neoplasms. Immunohistochemical evaluation and genetic testing are essential for a definitive diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.